Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

• by Andrea Surnit

• May 14, 2026

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

• by Nada Elbuluk, April W. Armstrong, Ronald Vender, Tina Bhutani, Lawrence Green, Laura K. Ferris, Vivian Laquer, Angela Moore, Jamie Weisman, Wenwen Zhang, Warren Winkelman, Melinda J. Gooderham

• May 16, 2026

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

• by Kathryn Wighton

• June 30, 2026

• 3 min

Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry

• by Jennifer Beecker, Lorne Albrecht, Ignacio Dei-Cas, Melinda Gooderham, Charles Lynde, Kim A. Papp, Paul Keown, Antonio Vieira, Mahmoud S. Farag, Marie Maguin, Tanya Zappitelli, Philip S. Helliwell

• July 21, 2026